Print Page     Close Window     

2019 Press Releases

Keyword Search
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013
02/07/19Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets
- Focusing resources on clinical readouts from late-stage microbiome programs for ulcerative colitis, C. difficile infection and planned immuno-oncology study - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced certain corporate changes to focus resources on its highest priority, clinical-stage microbiome therapeutic candidates. “We believe that microbiome therapeut... 
 Printer Friendly Version
01/15/19Seres Therapeutics Announces Chief Executive Officer Transition
- Eric Shaff, previously Chief Operating and Financial Officer, appointed President and Chief Executive Officer - - Roger J. Pomerantz, M.D., to continue to serve as Chairman - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 15, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Eric D. Shaff as President and Chief Executive Officer. Mr. Shaff, who is currently Chief Operating and Financial Officer, succeeds Roge... 
 Printer Friendly Version
01/03/19Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
– Recent FDA correspondence indicates this SER-287 Phase 2B study may support Biologics License Application (BLA) – – Company has received $40 million in milestone payments with Phase 2B study start – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2019-- Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that it has enrolled the first patient in its Phase 2B trial, ECO-RESET, evaluating microbiome development candidate SER-287 i... 
 Printer Friendly Version

© Seres Therapeutics. All Rights Reserved.